Background With higher valency pneumococcal vaccines on the horizon and new adult immunisation strategies under discussion, ...

SK Bioscience, Sanofi collaborate on next-gen pneumococcal vaccine development SK Bioscience and Sanofi join forces to ...

The Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection called pneumonia.

Serotype 3 pneumococcus (SPN3) presents a particular problem as there have been limited changes in incidence of this serotype despite a decade of immunisation programmes with PCV13 (1) and so SPN3 ...